Teleflex (TFX) stock dives on CEO exit and revenue forecast cut

New York, January 8, 2026, 14:02 EST — Regular session

Teleflex Incorporated shares slid 11.7% to $111.76 by mid-afternoon on Thursday after the medical device maker disclosed a CEO exit and trimmed its revenue forecast. The company said it was “the right time to transition leadership” as it pushes through a portfolio shift. Teleflex Investors

The drop matters because Teleflex is in the middle of a reset it has sold to investors as a cleanup job: slim down the company and lean harder into critical-care products. In December, Teleflex agreed to sell three businesses for $2.03 billion to sharpen its focus, with the deals expected to close in the second half of 2026. Reuters

On sales, Teleflex now expects full-year 2025 revenue of $3.270 billion to $3.278 billion, down from prior guidance of $3.305 billion to $3.320 billion. The company blamed softer-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia at year-end, plus delays in purchase orders in its OEM business, which makes products for other companies. Teleflex said the figures are preliminary, with the quarter-end close still under way, and it expects to report full fourth-quarter and full-year results in late February or early March. SEC

The leadership change was immediate. Liam Kelly left as president and chief executive at the end of Wednesday, and director Stuart Randle was appointed interim CEO on Thursday, an SEC filing showed. The board hired Spencer Stuart to run the search for a permanent CEO; the filing also said Randle will receive a $140,000-a-month stipend and a restricted stock grant valued at $1.5 million, due to be granted on January 13. SEC

The move snapped a run higher in the stock. Teleflex ended Wednesday at $126.53 after five straight sessions of gains, and it remains well below its 52-week high of $185.94 set on Jan. 27, 2025, MarketWatch data showed. MarketWatch

Elsewhere in medtech, the tape was calmer. Johnson & Johnson was down about 1%, Medtronic eased roughly 0.2%, while Boston Scientific traded up about 1.1%.

What could go wrong from here is fairly plain: if the year-end slowdown in balloon-pump demand stretches into the new quarter, or if delayed orders slip again, investors may start to treat Thursday’s revenue cut as a trend, not a bump. The CEO search adds another moving part; “interim” can drag on.

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

View all

Indian Stock Market Outlook: Gift Nifty Dip, Nasdaq Slide, Apple Gains, and Gold Rates Update
January 29, 2026, 10:53 PM EST. The Indian stock market witnessed mixed signals ahead of the Union Budget 2026. The Sensex rose 0.27% to 82,566.37, while the Nifty 50 gained 0.30% to 25,418.90, continuing a three-day rally. However, Gift Nifty traded at a discount, signaling a weaker start on Friday. In global cues, Asian markets advanced after U.S. President Trump hinted at a Federal Reserve chair announcement. U.S. stocks closed mostly lower; tech stocks dragged the Nasdaq down 0.72%. Apple shares inched up 0.72%, while Microsoft dipped 10%. The Indian market's near-term outlook remains cautious, with investors eyeing stock-specific movements ahead of budget announcements. Gold rates and geopolitical developments also influenced sentiment globally.